COMPOSITIONS FOR PREVENTING AND RELIEVING HANGOVER & LIVER DAMAGE WHICH OCCUR DUE TO ALCOHOL CONSUMPTION

Abstract

The present invention is a beverage for relieving and preventing harmful effects of alcohol consumption such as hangover and liver cell damage, which includes Curcuma longa Rhizome extract, L-Ornithine amino acid and Inositol as active ingredients. The curcumin extract standardized to 95% pure curcuminoides having at least 12% in the form of water dispersible micelle liquid. A method for beverage composition includes defined amount of curcumin extract, L-Ornithine Inositol and sugar syrup, wherein the curcumin extract, L-Ornithine and Inositol Powder added to the separately prepared sugar syrup under constant stirring. The present invention accelerates In vivo decomposition of alcohol after drinking, thereby helping to relieve and prevent harmful effects of alcohol such as hangover and liver damage.

Claims

1. A beverage composition, said composition comprising: 0.4952% curcumin extract, wherein the curcumin extract contains at least 6% curcuminoides; 0.4328% L-Ornithine; and 0.1197% Inositol; thereby the curcumin extract, L-Ornithine and Inositol mixed with separately prepared sugar syrup to complete said beverage composition.

2. The beverage composition as claimed in 1, wherein the L-Ornithine and Inositol used in powder form.

3. The composition as claimed in claim 1, wherein 0.02889% and 0.1032% of two natural flavor solution optionally added separately to the prepared beverage composition under constant stirring.

4. The beverage composition as claimed in claim 1, wherein the curcumin extract derived from Turmeric (Curcuma longa) Rhizome standardized to 95% pure curcuminoides having at least 12% in the form of micelle liquid.

5. The beverage composition as claimed in claim 1, wherein the curcumin extract is treated with amphiphilic liquid substance which make the curcumin extract in the form of micelle liquid form.

6. The beverage composition as claimed in claim 1, wherein said beverage composition is in liquid form.

7. The beverage composition as claimed in claim 1, wherein the curcumin extract, L-Ornithine and Inositol are the active Ingredients of the beverage composition.

8. The composition as claimed in claim 1, wherein 0.2931% of Amala (Indian gooseberry) extract and 0.2931% of Coconut water concentrate are used in the beverage composition.

9. The beverage composition as claimed in claim 1, wherein said beverage composition used for relieving and preventing liver cell damage and hangover.

10. The beverage composition as claimed in claim 1, wherein the method for preparing sugar syrup comprising: Adding 5.2% sugar, wherein 5.2% of sugar dissolved in purified water 92.03% of its total volume; and adding water soluble additive such as Citric acid 0.5503%, Sodium citrate 0.2119%, Potassium citrate 0.3284%, Sodium benzoate 0.0894%, Potassium sorbate 0.0894%, Stevia leaf extract 0.0179%, Xanthan gum 0.0825% one by one under stirring condition.

11. A method for beverage composition, wherein said method comprises: 0.4952% curcumin extract, wherein the curcumin extract contains at least 6% curcuminoides; 0.4328% L-Ornithine; 0.1197% Inositol; and Sugar syrup, wherein the curcumin extract, L-Ornithine and Inositol Powder added at the end to prepare sugar syrup under constant stirring.

12. The method for beverage composition as claimed in claim 10, wherein 0.02889% and 0.1032% natural flavor solution added separately to the prepared beverage composition under constant stirring.

13. The method for beverage composition as claimed in 10, wherein the L-Ornithine and Inositol used in powder form.

Description

BRIEF DESCRIPTION OF THE ACCOMPANYING DRAWING

[0047] The aforementioned aspects and other features of the present invention will be explained in the following description, taken in conjunction with the accompanying drawings, wherein:

[0048] FIG. 1 illustrates results of self-awareness efficacy assessment for relief in hangover.

[0049] FIG. 2 illustrates assessment results efficacy per individual hangover symptom.

OBJECTS OF THE INVENTION

[0050] The main objective of the invention to provide a beverage composition for relieving and preventing hangover.

[0051] Another objective of the present invention is to reduce the damage to liver and reduce hangover due to alcohol composition.

[0052] Further objectives, advantages and features of the present invention will become apparent from the detailed description provided herein below, in which various embodiments of the disclosed invention are illustrated by way of example and appropriate reference to accompanying drawings.

DETAILED DESCRIPTION OF THE INVENTION

[0053] While this invention is susceptible to embodiment in many different forms, there is shown in the drawings and will herein be described in detail specific embodiments, with the understanding that the present disclosure of such embodiments is to be considered as an example of the principles and not intended to limit the invention to the specific embodiments shown and described. In the description below, like reference numerals are used to describe the same, similar or corresponding parts in the several views of the drawings. This detailed description defines the meaning of the terms used herein and specifically describes embodiments in order for those skilled in the art to practice the invention.

Definition

[0054] The terms a or an, as used herein, are defined as one or as more than one. The term plurality, as used herein, is defined as two or as more than two. The term another, as used herein, is defined as at least a second or more. The terms including and/or having, as used herein, are defined as comprising (i.e., open language). The term coupled, as used herein, is defined as connected, although not necessarily directly, and not necessarily mechanically.

[0055] The term comprising is not intended to limit inventions to only claiming the present invention with such comprising language. Any invention using the term comprising could be separated into one or more claims using consisting or consisting of claim language and is so intended. The term comprising is used interchangeably used by the terms having or containing.

[0056] Reference throughout this document to one embodiment, certain embodiments, an embodiment, another embodiment, and yet another embodiment or similar terms means that a particular feature, structure, or characteristic described in connection with the embodiment is included in at least one embodiment of the present invention. Thus, the appearances of such phrases or in various places throughout this specification are not necessarily all referring to the same embodiment. Furthermore, the particular features, structures, or characteristics are combined in any suitable manner in one or more embodiments without limitation.

[0057] The term or as used herein is to be interpreted as an inclusive or meaning any one or any combination. Therefore, A, B or C means any of the following: A; B; C; A and B; A and C; B and C; A, B and C. An exception to this definition will occur only when a combination of elements, functions, steps or acts are in some way inherently mutually exclusive.

[0058] As used herein, the term one or more generally refers to, but not limited to, singular as well as plural form of the term.

[0059] The drawings featured in the figures are for the purpose of illustrating certain convenient embodiments of the present invention and are not to be considered as limitation there to. Term means preceding a present participle of an operation indicates a desired function for which there is one or more embodiments, i.e., one or more methods, devices, or apparatuses for achieving the desired function and that one skilled in the art could select from these or their equivalent in view of the disclosure herein and use of the term means is not intended to be limiting.

[0060] The present invention is a beverage for relieving and preventing harmful effects of alcohol consumption such as hangover and liver cell damage, which includes Turmeric (Curcuma longa) Rhizome extract, L-Ornithine HCL (an amino acid) and Inositol as active ingredients, prepared using unique process.

[0061] The present inventors have thus taken various In-vivo trials to establish this hypothesis and found that the beverages made with Curcumin, L-Ornithine and Inositol is highly effective in preventing hangover and liver cell damage.

[0062] The present invention relates to a beverage for relieving and preventing hangover, including the foregoing composition, more specifically, a method for preparation of the composition for relieving and preventing hangover according to the present invention may include the following:

[0063] In the present embodiment of the present invention the beverage composition prepared by first preparing sugar syrup which is made by following process. 5.1587% of sugar is to be dissolved in purified water 92.03% of its total volume. All water-soluble additives such as Citric acid 0.5503%, Sodium citrate 0.2119%, Potassium citrate 0.3284%, Sodium benzoate 0.0894%, Potassium sorbate 0.0894%, Stevia leaf extract 0.0179%, Xanthan gum 0.0825% are to be added one by one under stirring condition. Curcumin micelle liquid (with at least 6% curcuminoides) 0.4952%, L-Ornithine powder 0.4328% and Inositol powder 0.1197% are to be added at the end to prepare beverage liquid. Separately, 0.02889% and 0.1032% of two natural flavour solutions are to be added in prepared beverage liquid under stirring and mix well to attain homogenous ready to drink beverage.

[0064] In another embodiment of the present invention the beverage composition prepared by first preparing sugar syrup which is made by following process. 5.1587% of sugar is to be dissolved in purified water 92.03% of its total volume. All water-soluble additives such as Citric acid 0.5503%, Sodium citrate 0.2119%, Potassium citrate 0.3284%, Sodium benzoate 0.0894%, Potassium sorbate 0.0894%, Stevia leaf extract 0.0179%, Xanthan gum 0.0825% are to be added one by one under stirring condition. Curcumin micelle liquid (with at least 6% curcuminoides) 0.4952%, Amala (Indian gooseberry) extract 0.2139%, Coconut water concentrate 0.2139% L-Ornithine powder 0.4278% and Inositol powder 0.1197% are to be added at the end to prepare beverage liquid. Separately, 0.02889% and 0.1032% of two natural flavour solutions are to be added in prepared beverage liquid under stirring and mix well to attain homogenous ready to drink beverage.

[0065] In order to attain hangover relief (and prevention) efficacy as described above, a total amount of the beverage composition comprising major active ingredients such as Curcumin (with at least 6% curcuminoides), L-Ornithine and Inositol powder proposed according to the present invention, for an adult weighing 70 kg average. The prepared composition may be taken without particular limitations. The number of taking the composition may be limited as per the consumption limit of additives such as polyols, preservatives, sweetening agents, electrolytes etc.

[0066] Using the active combination according to the present invention, in addition to beverages (or drinks), various formulations for relieving hangover such as liquid preparations (gels, extract), pills, powder, tablets, capsules, or the like may be manufactured for oral administration.

[0067] In another embodiment of the present invention the Curcumin may be in the form of an extract. Such an extract has the advantage of allowing the easy introduction of the active curcuminoids of the turmeric in the beverage. The extract may be prepared by any method of extraction known in the art. The extract powder may be further purified to achieve 95% pure curcuminoids. This specific turmeric extract further processed with this extract a micelle liquid form and allows it to provide stable water dispersion which essentially improves its bioavailability by many folds in human intestine during digestion.

[0068] In embodiments, the Curcumin micelle liquid provides about 12 mg of 95% pure curcuminoids per 70 ml of the beverage.

[0069] In further embodiment of the present invention the L-Ornithine and Inositol may be in the form of a powder. These powders may be pharmaceutical grade from the commerce.

[0070] The beverage apart from 3 actives may contain natural or artificial sweetener, polyol such as Sorbitol or Erythritol, Citric acid as acidity regulator, Sodium citrate and Potassium citrate as electrolytes, permitted preservatives, thickener, natural and natural identical flavour and water as carrier.

[0071] In another embodiment the beverage apart from 5 actives may contain natural or artificial sweetener, polyol such as Sorbitol or Erythritol, Citric acid as acidity regulator, Sodium citrate and Potassium citrate as electrolytes, permitted preservatives, thickener, natural and natural identical flavour and water as carrier.

DESCRIPTION OF THE DRAWINGS

[0072] FIG. 1 illustrates assessment results of improvement in overall hangover extents after taking a composition for relieving and preventing hangover according to the present invention before drinking alcohol, based on results of self-awareness efficacy tests in relation to hangover relief using the composition for relieving and preventing hangover according to the present invention.

[0073] FIG. 2 illustrates assessment results of improvement in different hangover symptoms after taking a beverage for relieving and preventing hangover according to the present invention before drinking alcohol.

PRACTICAL EMBODIMENTS OF THE PRESENT INVENTION WILL BE DESCRIBED IN DETAIL ACCORDING TO THE FOLLOWING EXAMPLES

Example 1

[0074] Preparation of Turmeric (Curcuma longa L) Rhizome Extract (with at Least 6% Curcuminoides) in Liquid Form.

[0075] Curcumin derived from Turmeric (Curcuma longa L) Rhizome extract (with at least 6% curcuminoides), L-Ornithine and Inositol powder are procured from commercial supply.

Example 2

[0076] Preparation of a Beverage Composition for Relieving Hangover Before and after Drinking

[0077] Beverage for the present invention may be prepared by first preparing Sugar syrup which is made by following process. 5.1587% of sugar is to be dissolved in purified water 92.03% of its total volume. All water-soluble additives such as Citric acid 0.5503%, Sodium citrate 0.2119%, Potassium citrate 0.3284%, Sodium benzoate 0.0894%, Potassium sorbate 0.0894%, Stevia leaf extract 0.0179%, Xanthan gum 0.0825% are to be added one by one under stirring condition. Curcumin micelle liquid (with at least 6% curcuminoides) 0.4952%, L-Ornithine powder 0.4328% and Inositol powder 0.1197% are to be added at the end to prepare beverage liquid. Separately, 0.02889% and 0.1032% of two natural flavour solutions are to be added in prepared beverage liquid under stirring and mix well to attain homogenous ready to drink beverage. Thereafter, the obtained product was filled in suitable container, labelled and packaged, thereby producing a hangover relief beverage (drink).

Experimental Example 1

[0078] Clinical Study Design & Duration:

[0079] The present study is a double blind, in-house, randomized, two-arm parallel, placebo-controlled study for evaluation of the efficacy and safety of investigational beverage product in people with hangover. Person selected given the willingness to undergo alcohol drinking aged between 30 to 50 years were selected for the study on the basis of inclusion criteria. Total duration of the study for a patient was not exceeding 10 days. Enrolled Thirty (30) Healthy male volunteers were divided in to two groups, 15 volunteers in each group.

[0080] Group A (Test Group) was given health drink of SHOT-X of 70 ml 30 minutes after the last drink. [All volunteers took nearly 140 ml (1.8-2 ml/kg) of whisky (42.8% w/v) of the same brand and batch. The duration of drink was 1 hour.]

[0081] Group B (Placebo Group) was given 70 ml of PLACEBO drink containing no actives. 30 minutes after the last drink. [All volunteers took nearly 140 ml (1.8-2 ml/kg) of whisky (42.8% w/v) of the same brand and batch. The duration of drink was 1 hour.]

[0082] Criteria for the Assessment:

[0083] The patients were evaluated for primary endpoints & secondary endpoints parameters.

[0084] Primary Endpoints: [0085] 1. ALT, AST and ALP: Baseline, 2 and 10 hours of formulation [0086] 2. ALDH (Acetaldehyde Dehydrogenase): Baseline, after 0, 2 hours and 10 hours of the formulation [0087] 3. Blood Aldehyde: Baseline, after 0, 2 hours and 10 hours of the formulation [0088] 4. Blood Alcohol: Baseline, after 0, 2 hours and 10 hours of the formulation

[0089] Secondary Endpoints: [0090] 1. Questionnaire to ask to understand the level of hangover [0091] 2. Walk test on drawn single line on the floor (15 meters) to understand the level of hangover [0092] 3. Incidence and rate of adverse events, if any

[0093] Statistical Analysis:

[0094] Data analysis was performed using SAS statistical software version 9.1.3 at 5% level of significance. Values were expressed in MeanSD. p0.05 was considered as statistically significant p0.01 was considered as statistically Highly significant and p0.001 was considered as Very highly significant.

RESULTS & DISCUSSION

[0095] A total number of 30 subjects were involved in this study and all patients had completed the study. No drop-out was observed.

[0096] Effect on Alanine Amino Transferase (ALT) Level:

TABLE-US-00002 TABLE 1 Effect on Alanine amino transferase (ALT) level in different groups Groups Baseline 2 Hours 10 hours Group A 47.22 9.87 40.20 11.11* 38.07 9.42 Group B 41.53 10.43 38.80 8.55 40.80 8.74

[0097] Paired t-test was applied within group where n=15 for each group; Values were expressed in MeanSEM. Different significant levels were marked as *p<0.05, .sup.#p<0.01, .sup.##p<0.001. The results output for Alanine amino transferase (ALT) showed that p value obtained for Baseline vs 2 hours for Group A was found to be 0.0130. This clearly suggests that a statistically significant change has been observed from Baseline to 2 hours values for Group A whereas no statistically significant change has been noticed in Group B. There was no statistically significant change from Baseline to 10 hours values for Group A and Group B values of Alanine amino transferase. (Table 1). Normally, AST level in our blood are low. If liver is damaged AST level is rise in blood. Data of Table 1 directs that Test drink Shot-X was able to make significant reduction in AST level which shows the liver protective property of the Shot-X.

[0098] Effect on Aspartate Aminotransferase (AST) Level:

TABLE-US-00003 TABLE 2 Effect on Aspartate aminotransferase (AST) level in different groups Groups Baseline 2 Hours 10 hours Group A 25.05 5.30 24.87 9.80 24.20 7.56 Group B 24.73 10.56 22.87 9.26 24.40 8.08

[0099] Paired t-test was applied within group where n=15 for each group; Values were expressed in MeanSEM. Different significant levels were marked as *p<0.05, .sup.#p<0.01, .sup.##p<0.001. Null difference was observed in Aspartate aminotransferase (AST) level of both the groups at baseline, 2 hours & 10 hours values. It indicates no effect of test drink on this parameter. (Table 2).

[0100] Effect on Alkaline Phosphatase (ALP) Level:

TABLE-US-00004 TABLE 3 Effect on Alkaline phosphatase (ALP) level in different groups Groups Baseline 2 Hours 10 hours Group A 93.39 17.15 20.67 7.93.sup.## 36.60 6.20.sup.## Group B 84.73 23.67 61.20 7.06.sup.# 62.00 5.50.sup.#

[0101] Paired t-test was applied within group where n=15 for each group; Values were expressed in MeanSEM. Different significant levels were marked as *p<0.05, .sup.#p<0.01, .sup.##p<0.001. A significant reduction was observed in Alkaline phosphatase (ALP) level of both groups in comparison to baseline value however Group A showed highly significant change as compared to Group B. Significant increase in ALP level at 10 hours in comparison of 2 hours value shows signs of recovery and effect of test drink. Similar recovery was also observed in Placebo group but in lesser proportion. (Table 3)

[0102] On ALDH (Acetaldehyde Dehydrogenase) & Blood Aldehyde:

TABLE-US-00005 TABLE 4 Effect on ALDH (Acetaldehyde Dehydrogenase) level in different groups Groups Baseline 2 Hours 10 hours Group A 62.47 3.27 118.83 12.34.sup.## 88.82 5.40.sup.## Group B 62.93 4.57 88.17 7.13.sup.## 74.37 5.11.sup.##

[0103] Paired t-test was applied within group where n=15 for each group; Values were expressed in MeanSEM. Different significant levels were marked as *p<0.05, .sup.#p<0.01, .sup.##p<0.001. After consumption of alcohol Acetaldehyde dehydrogenase (ALDH) level is increased and over the period of time metabolism and excretion of alcohol take place its level down. Level of ALDH may vary based on frequency of alcohol consumption, volume of alcohol, metabolism rate of an individual, age & sex etc. Statistically significant rise was observed from Baseline to 2 hours values for Group A and Group B and at 10 hours these values were significantly reduced near to baseline value. (Table 4)

TABLE-US-00006 TABLE 5 Effect on Blood Aldehyde level in different groups Groups Baseline 2 Hours 10 hours Group A 1.470 0.36 3.155 0.15.sup.## 1.379 0.34.sup.## Group B 1.578 0.26 3.57 0.25.sup.## 2.873 0.24.sup.#

[0104] Paired t-test was applied within group where n=15 for each group; Values were expressed in MeanSEM. Different significant levels were marked as *p<0.05, .sup.#p<0.01, .sup.##p<0.001. The increase in ALDH levels directly lead to decrease in Blood Aldehyde levels and thus hangover effect is reduced. Elevated blood acetaldehyde causes facial flushing, severe headache, palpitations, tachycardia, hypertension, respiratory distress, nausea and vomiting which are common symptoms of hangover. Significant rise in ALDH level in test group was directly correlated with decrease in blood aldehyde level which indicates effect of Shot-X on hangover. This clear correlation was found with the clinical data in Placebo group as we have observed 14 subjects to have hangover in Placebo group and also their individual Blood aldehyde levels were found on higher side i.e. their ALDH values were on the lower side which lead to mild hangover. This is due to the active compound of Shot-X. It is augmenting the normal physiological phase-II detoxification by increasing the level of ALDH thereby causing a significant reduction in blood aldehyde levels which explains the absence of hangover in group of subjects who were dozed with Shot-X in comparison to Placebo.

[0105] Effect on Blood Alcohol Level:

TABLE-US-00007 TABLE 6 Effect on Blood Alcohol level in different groups Groups Baseline 2 Hours 10 hours Group A 0.0021 0.0008 0.4053 0.0608.sup.## 0.0018 0.0015* Group B 0.0024 0.0011 0.4180 0.0517.sup.## 0.0033 0.0016*

[0106] Paired t-test was applied within group where n=15 for each group; Values were expressed in MeanSEM. Different significant levels were marked as *p<0.05, .sup.#p<0.01, .sup.##p<0.001. Data of Table 6 indicates that no significant difference was observed in alcohol levels of Group A & Group B at baseline. But it was clearly evidenced that after 10 hours mean blood alcohol levels were much better controlled by Group A in comparison to Group B.

[0107] Effect on Hangover Symptoms & Walk Test:

[0108] Highly significant effect was noticed during the evaluation of test drink Shot-X on hangover symptoms. In Group A, Hangover symptoms like Feeling thirsty, Stomach ache, Feeling nausea, Heart palpitations, Loss of appetite and Feeling tired were not observed in any subjects. Only one subject felt headache & dizziness in Group A. Overall 93.33% subjects were found no hangover where in placebo group i.e. in Group B, 86.66% subjects were reported with mild to moderate hangover during walk test.

CONCLUSION

[0109] From the present data, it can be concluded that Shot-X is effectively able to increase the level of Acetaldehyde Dehydrogenase (ALDH) and thereby decreasing the Blood Aldehyde levels which will alleviate the symptoms of hangover. Shot-X is also helpful in reducing liver enzymes which shows its hepato-protective activity. As far its safety concern, there was no adverse events were observed during the clinical trial. It proves that Shot-X a liquid curcumin based oral drink is safer and efficient to diminish hangover symptoms caused due to alcohol intoxication.

Experimental Example 2

[0110] Hangover Self-Awareness Efficacy Verification Test

[0111] A test procedure for hangover self-awareness efficacy was conceived and practically conducted on the basis of hangover assessment question items disclosed in a foreign document (Pittler, M. H. et al. CMAJ* 2003:169:1269-1273, Canadian medical association or its licensors), and an assessment procedure and data for hangover extents which are applied to Research report regarding development of hangover relieving efficacy protocol by the Korean food and drug administration (KFDA).

[0112] Age and gender distributions of participants for the present test are shown in TABLE 7.

Description of the Tables

[0113] TABLE 7 illustrates distribution of all 15 male Test panelists for the Hangover Self-Awareness Efficacy Verification Test.

TABLE-US-00008 Age wise distribution Male 29 years old or less 4 30 to 34 years old 6 35 to 39 years old 3 40 to 44 years old 2 Total 15

[0114] In respective test groups, all male participants had an average drinking capacity of 3 bottles.

[0115] After providing 70 ml (1 bottle) of the beverage composition for relieving and preventing hangover prepared in Example 2 according to the present invention to each of 15 men, the participants were allowed to sufficiently drink within individual drinking capacities. The following day after drinking, a questionnaire (that is, checklist) in regard to self-awareness for hangover relieving efficacy was given to each participant to investigate hangover states and the participants replied to questions on the checklist, to thereby conduct question assessment of self-awareness efficacy for hangover relief.

[0116] Ingredients of the composition for relieving and preventing hangover developed according to the present invention, which was used in the foregoing assessment, are shown in TABLE 8 (see Example 2). In order to evaluate self-awareness efficacy for hangover relief, the checklist used in the present invention is shown in TABLE 9.

[0117] TABLET 8: Table 8 illustrates the Composition of the beverage for relieving and preventing hangover taken by test panelists.

[0118] Composition of the beverage for relieving and preventing hangover taken by test panelists was as followed.

TABLE-US-00009 Ingredients % 70 ml UOM Curcumin (6% Curcuminoids) liquid extract 0.4952 360.00 Mg L-Ornithine HCL 0.4328 314.60 Mg Inositol 0.1197 87.00 Mg Sugar, Granulated 5.1587 3750.00 Mg Stevia leaf extract 0.0179 13.00 Mg Citric acid 0.5503 400.00 Mg Potassium Sorbate 0.0894 65.00 Mg Potassium citrate 0.3284 238.70 Mg Sodium Benzoate 0.0894 65.00 Mg Sodium Citrate 0.2119 154.00 Mg Natural Orange Cream Flavour 0.2889 210.00 Mg Natural Orange Sweet Juicy Flavour 0.1032 75.00 Mg Purified Water Q.S. Q.S.

[0119] TABLE 9 illustrates the Checklist for assessment of self-awareness efficacy for hangover relief.

[0120] Checklist for assessment of self-awareness efficacy for hangover relief

TABLE-US-00010 Hangover relieving Hangover extent No ----------- > efficacy Serious Symptoms (Yes, No) 1 2 3 4 5 Thirst Drowsiness Vomiting/nausea/ feeling sick Headache Stomach burn/ abdominal pain/ stomach pain Myalgia Short time blackout Hunger Fatigue/tiredness Concentration decrease/ concentration disorder Tremor of hands and feet Impatience/anger Irritability Fuzziness/spaced-out feeling Diarrhoea Depression Languor Overall hangover symptoms

[0121] Assessment standards for scores given by participants

(1) No hangover: no difficulty (or trouble) in daily life
(2) Little hangover: There is scarcely any difficulty (or trouble) in daily life
(3) Being usual: hangover is less than ordinary times and no difficulty (or trouble) in daily life
(4) General hangover: difficulty (or trouble) in daily life
(5) Heavy hangover: hangover is serious to have difficulty (or trouble) in daily life

[0122] As a result of self-awareness efficacy assessment, it was found that improvement effects (decrease in hangover symptoms) were recorded in most question items regarding such hangover symptoms when the participants took the composition for relieving and preventing hangover according to the present invention. Specifically, with regard to important symptom items showing high response rate (75% or more) such as fatigue, headache, thirst, stomach burn/stomach pain, drowsiness, vomiting, etc., among hangover assessment items, the participants reported good effects in a range of at least 70% and up to 85%. Therefore, it can be understood that the inventive composition for relieving and preventing hangover exhibits remarkably improved effects in relieving hangover. With regard to other items such as tremor of the hand, impatience, irritability, languor, Myalgia, etc., the inventive composition also exhibited improved effects. However, since the foregoing items have relatively decreased response rate by the participants, compared to other items, it was considered that symptoms in these items are not major hangover symptoms. Detailed test results are shown in TABLE 4.

[0123] TABLE 10: illustrates the detailed results of Table 7, Table 8 and Table 9.

TABLE-US-00011 Stomach Black Section Thirst Drowsiness Vomiting Headache burn/pain Fatigue Myalgia out Total Avg. extent 2.66 2.28 1.97 2.47 1.58 2.57 1.25 1.55 15 of cognitive symptoms Avg. 90% 80% 80% 81% 77% 81% 78% 79% Response rate % Tremor Concentration of the Section Hunger disorder hand Impatience Irritability Fuzziness Diarrhea Languor Total Avg. 1.90 1.99 1.07 1.52 1.86 2.06 1.91 1.32 15 extent of cognitive symptoms Avg. 77% 81% 75% 82% 76% 83% 83% 77% Response rate %

[0124] Moreover, as a result of confirming whether the composition for relieving and preventing hangover according to the present invention has effects of relieving or improving overall hangover symptoms to all 15 male participants who participated in the present test recognized hangover relieving efficacy of the inventive composition. Consequently, it can be identified that products developed according to the present invention may have excellent effects in relieving hangovers.

[0125] As apparent from the foregoing, the beverage composition according to the present invention may exhibit excellent effects in hangover relief and prevention, as demonstrated from self-awareness efficacy tests.

[0126] Although the preferred embodiments of the present invention have been disclosed for illustrative purposes, those skilled in the art will appreciate that various modifications, additions and substitutions are possible, without departing from the scope and spirit of the invention as disclosed in the accompanying claims.

[0127] Further objectives, advantages and features of the present invention will become apparent from the detailed description provided herein below, in which various embodiments of the disclosed present invention are illustrated by way of example and appropriate reference to accompanying drawings. Those skilled in the art to which the present invention pertains may make modifications resulting in other embodiments employing principles of the present invention without departing from its spirit or characteristics, particularly upon considering the foregoing teachings. Accordingly, the described embodiments are to be considered in all respects only as illustrative, and not restrictive, and the scope of the present invention is, therefore, indicated by the appended claims rather than by the foregoing description or drawings. Consequently, while the present invention has been described with reference to particular embodiments, modifications of structure, sequence, materials and the like apparent to those skilled in the art still fall within the scope of the invention as claimed by the applicant.